EN DE
Watch Pulmatrix, Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Pulmatrix, Inc (PULM) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Pulmatrix, Inc stock $0.59, price $1.42, that is 58.5% below the price, quality 49 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PI Pulmatrix, Inc logo Thin data Nov 19, 2026

Pulmatrix, Inc

PULM · US

Far too expensive (fair value 59% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Quality 49/100 
Mixed vs. peers (3/6) 
Fair value $0.59 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −0.3 %/yr in USD) 
Negative free cash flow 
Narrow moat 9/100
Thin data 
Estimate
Watch Pulmatrix, Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$20.00 $1.19 Fair Value $0.59 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.

How to read this chart

60‑month range $1.19 – $20.00 · fair‑value band $0.44 – $0.73 · the $1.42 price screens above the $0.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 19, 2026.

Follow Pulmatrix in your weekly email

Every Wednesday you see whether Pulmatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.

Show moreShow less

The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.

It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Stock analysis

Pulmatrix, Inc (PULM) currently trades at $1.42, while our estimate is $0.59, 59% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.44 (bear) to $0.73 (bull), the price of $1.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Pulmatrix, Inc reported revenue of $0 in FY2025 versus $5.2M in FY2021. Reported net income was −$5.2M in FY2025.

Key figures

Market cap $5.2M Micro · EPS (TTM) $-1.20 · Return on equity −143% · Return on assets (EBIT) −69.4% (5-year average) · Revenue (TTM) $3.0K · Free cash flow −$5.4M · Net cash $4.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 70% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −59%, PULM screens richer than that median.

Fair Value

Bear $0.44 Fair Value $0.59 Bull $0.73
Price $1.42 · Downside -58.5%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 68
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 1/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+7.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−261.6% (2019) → −125.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PULM screens overvalued: fair value 59% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pulmatrix, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −58.5% · Bottom 25%
Profitability
Return on assets −124.7% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.36× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 2
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $923.34 $1,275.02 +38% vs PULM
Vertex Pharmaceuticals Incorporated VRTX $520.66 $587.62 +13% vs PULM
Samsung Biologics Co 207940 ₩1,375,000 ₩1,512,500 +10% vs PULM
argenx SE ARGX $942.04 $908.40 −4% vs PULM
CSL Limited CSL A$197.29 A$188.80 −4% vs PULM
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs PULM
Moderna, Inc MRNA $199.33 $122.98 −38% vs PULM
Revolution Medicines, Inc RVMD $159.43 $83.12 −48% vs PULM
Celltrion, Inc 068270 ₩215,000 ₩74,574 −65% vs PULM
Royalty Pharma plc RPRX $67.72 $19.01 −72% vs PULM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pulmatrix, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pulmatrix, Inc Fair Value". https://www.fairvalue-calculator.com/stock/PULM

Frequently asked questions

Is Pulmatrix, Inc (PULM) overvalued or undervalued?
As of Nov 19, 2026, our estimate of fair value is $0.59 versus a price of $1.42, about 59% lower (overvalued).
What is the fair value of PULM?
Our estimate for Pulmatrix, Inc is $0.59 (as of Nov 19, 2026), built from audited fundamentals. The current price: $1.42.
What is the quality score of PULM?
Pulmatrix, Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pulmatrix, Inc (PULM)?
We do not set a price target; the yardstick is our estimate of $0.59 (as of Nov 19, 2026). Cautious scenario $0.44, optimistic scenario $0.73. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Pulmatrix, Inc stock forecast for 2026?
Our estimate puts fair value at $0.59, about 59% lower versus a price of $1.42 (overvalued). Cautious scenario $0.44, optimistic scenario $0.73. The calculation is refreshed regularly with new filings.
What is the revenue of Pulmatrix, Inc (PULM)?
Pulmatrix, Inc reported trailing-twelve-month revenue of about $3.0K (latest available figure, as of Nov 19, 2026).
What is the intrinsic value of Pulmatrix, Inc (PULM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pulmatrix, Inc it is $0.59 per share (as of Nov 19, 2026), against a price of $1.42.
Is Pulmatrix, Inc stock overvalued or undervalued in 2026?
As of Nov 19, 2026, PULM trades above its calculated fair value: price $1.42, fair value $0.59, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PULM?
No. The price is what the market pays today ($1.42); the fair value is what the company's own numbers justify ($0.59). For Pulmatrix, Inc the two are $0.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pulmatrix, Inc worth?
The market values Pulmatrix, Inc at about $5.2M (market capitalisation, as of Nov 19, 2026). Per share that is $1.42; our models calculate a fair value of $0.59 per share.
What do the bullish and bearish scenarios say about PULM?
Our models span a range for Pulmatrix, Inc: cautious scenario $0.44, base $0.59, optimistic $0.73 per share (as of Nov 19, 2026, price $1.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pulmatrix, Inc (PULM)?
Balance-sheet figures for Pulmatrix, Inc (as of Nov 19, 2026): return on equity −143.1%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is PULM from its 52-week high?
Pulmatrix, Inc trades at $1.42, about 70% below its 52-week high of $4.70 and 19% above the low of $1.19 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of $0.59 is for.
Which stocks are comparable to Pulmatrix, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pulmatrix, Inc stock attractive at the current price?
The data as of Nov 19, 2026: price $1.42, calculated fair value $0.59 (−59%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Pulmatrix, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pulmatrix, Inc (PULM)?
The closing price on Nov 19, 2026 was $1.42. Our estimate is $0.59, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pulmatrix, Inc right now?
The price sits above even our optimistic bull case ($0.73). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Pulmatrix, Inc

How large is the market capitalisation of Pulmatrix, Inc (PULM)?
The market capitalisation of Pulmatrix, Inc is $5.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pulmatrix, Inc (PULM)?
Earnings per share at Pulmatrix, Inc are $-1.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pulmatrix, Inc (PULM)?
The return on equity (ROE) of Pulmatrix, Inc is −143% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pulmatrix, Inc (PULM)?
On an EBIT basis the return on assets of Pulmatrix, Inc is −69.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Pulmatrix, Inc (PULM) generate?
The free cash flow of Pulmatrix, Inc is −$5.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pulmatrix, Inc (PULM) hold?
Pulmatrix, Inc holds more cash than debt, $4.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Pulmatrix, Inc in the live analysis

One click puts Pulmatrix, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.